250
Participants
Start Date
January 31, 2015
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
zenocutuzumab (MCLA-128)
full length IgG1 bispecific antibody targeting HER2 and HER3
Niguarda Cancer Centre, Milan
START Hospital Fundación Jiménez Diaz, Madrid
START Hospital Universitario Madrid Sanchinarro, Madrid
Karmanos Cancer Center, Detroit
Institut Gustave Roussy, Paris
Mayo Clinic, Phoenix
The Oncology Institute of Hope and Innovation, Cerritos
University of California Irvine, Irvine
Stanford University, Palo Alto
Sharp Memorial Hospital, San Diego
Georgetown University, Washington D.C.
Memorial Cancer Institute, Hollywood
Cancer Specialists of North Florida, Jacksonville
Mayo Clinic, Jacksonville
Emory Winship Cancer Institute, Atlanta
Northwest Oncology & Hematology, Rolling Meadows
Dana Farber Cancer Center, Boston
Mayo Clinic, Rochester
Billings Clinic Cancer Center, Billings
St. James Healthcare, Butte
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Philadelphia
Averra Medical Group, Sioux Falls
The University of Texas MD Anderson Cancer Center, Houston
Huntsman Cancer Institute, Salt Lake City
Utah Cancer Specialists, Salt Lake City
Hematology-Oncology Specialist of Fredericksburg, Fredericksburg
Virginia Mason Hospital & Seattle Medical Center, Seattle
Hematology Oncology Associates, Spokane
Northwest Medical Specialties, Tacoma
Salzburger Universitatsklinikum, Salzburg
UZ Leuven, Leuven
Rigshospitalet, Copenhagen
Centre Leon Berard, Lyon
Hospital Louis Pradel, FR, Lyon
Hopital Cochin, Paris
Hopital Curie, Paris
Asklepios Klinik Altona, Hamburg
Asklepios Kliniken Hamburg GmbH, Hamburg
Deutsches Krebsforschungszentrum, Heidelberg
Shaare Zedek Medical Center, Jerusalem
Sheba Medical Center, Tel Aviv
Ospedale San Raffaele, Milan
Istituti Fisioterapici Ospitalieri, Roma
National Cancer Center Hospital, Chūōku
St. Marianna University School of Medicine Hospital, Kawasaki
Osaka International Cancer Institute, Osaka
National Cancer Center East, Tokyo
Amsterdam Medical Center, Amsterdam
Radboud University Medical Center, Nijmegen
National Cancer Centre of Singapore PTE LTD, Singapore
Samsung Medical Center, Seoul
Seoul National University College of Medicine, Seoul
Severance Hospital- Yonsei Cancer Center, Seoul
Hospital 12 de Octubre, Madrid
Clínica Universidad de Navarra, Pamplona
Instituto Valenciano Oncologia, Valencia
Karolinska Universitetssjukhuset, Solna
National Taiwan University Hospital 7, Taipei
Sarah Cannon Research Institute, London
Princess MargaretCancer Centre, Toronto
NKI, Amsterdam
University Hospital Oslo, Oslo
Vall D'Hebron Institute of Oncology (VHIO), Barcelona
Lead Sponsor
Partner Therapeutics, Inc.
INDUSTRY